Hence, focusing on anti-ferroptosis therapy may help reverse the detrimental effects of elevated insulin in MASLD mediated via ferroptosis, such as Malic Enzyme 1 (ME1) [51], although this requires further investigations using population-based studies. The gene discussed is ME1; the disease is metabolic dysfunction-associated steatotic liver disease.